Collection
Molecular imaging in cardiac amyloidosis
Cardiac amyloidosis is a complex and often underdiagnosed pathological condition, which poses significant challenges in both its detection and management. Molecular imaging has gained interest in the latest year, due to its capability to allow for an early and precise diagnosis of cardiac amyloidosis as well as for its characterization. Furthermore, recent evidence show the potential for a prognostic stratification. In fact, molecular imaging, including positron emission tomography (PET) and single photon emission computed tomography (SPECT), enables specific insights in the processes underlying amyloid deposition within the heart, thus providing important information on disease progression and treatment response. This collection aims to explore pre-clinical research and clinical applications of molecular imaging in the scenario of cardiac amyloidosis, highlighting its important role in improving patients’ outcome and guiding therapeutic strategies.
Editors
-
Federico Caobelli
PD Dr. med. Federico Caobelli, Bern, Switzerland
-
Christoph Rischpler
Prof. Dr. med Christoph Rischpler, Stuttgart, Germany
Articles (7 in this collection)
-
-
Nuclear medicine practice for the assessment of cardiac sarcoidosis and amyloidosis. A survey endorsed by the EANM and EACVI.
Authors (first, second and last of 17)
-
-
Treatment response assessment in transthyretin-related cardiac amyloidosis: an emerging clinical indication of bone-seeking radiopharmaceuticals?
Authors (first, second and last of 5)
-
Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?
Authors (first, second and last of 16)
-
Prevalence of ATTR-CA and high-risk features to guide testing in patients referred for TAVR
Authors (first, second and last of 13)
-
Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: A systematic review
Authors (first, second and last of 8)
